SCHEMBL29951696

SCHEMBL29951696

Cc1cccc(C=O)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL230251 1.00
Alcohol SCHEMBL16679847 0.90 MEN1 (0.46)
2-Pyridinecarboxaldehyde SCHEMBL3431231 0.87 ALDH1A1 (0.47)
Glycine SCHEMBL8213980 0.84 ALDH1A1 (0.45)
SCHEMBL9868200 0.84 SMN1; SMN2 (0.41)
SCHEMBL7527384 0.82 ALDH1A1 (0.40)
SCHEMBL303150 0.82 CCR1 (0.55)
SCHEMBL4712658 0.80 RAB9A (0.76)
SCHEMBL1957722 0.80 TERT (0.38)
SCHEMBL18773795 0.80 HTT (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3723754-B1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME LLC (US) 2026-05-13 EP claimed
CN-120058554-A Epoxy curing agent containing double dynamic bonds, preparation method thereof, degradable and reconfigurable epoxy resin material and preparation method thereof 西安智聚复合材料科技有限公司 2025-05-30 CN claimed
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
CN-120058554-A Epoxy curing agent containing double dynamic bonds, preparation method thereof, degradable and reconfigurable epoxy resin material and preparation method thereof 西安智聚复合材料科技有限公司 2025-05-30 CN disclosed
CN-119930711-A Chiral ferrocene skeleton tetradentate ligand and application thereof in asymmetric hydrogenation reaction 中国人民解放军空军军医大学 2025-05-06 CN disclosed
US-20250051316-A1 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2025-02-13 US disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 EP disclosed
EP-4428128-A1 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-09-11 EP disclosed
CN-118475553-A Iron-catalyzed cis-dihydroxylation of quinones with high enantioselectivity 港大科桥有限公司 2024-08-09 CN disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
US-20230322704-A1 COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-10-12 US disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 WO disclosed
US-11718588-B2 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis GALAPAGOS NV (BE) 2023-08-08 US disclosed
US-11530191-B2 Compounds and uses thereof for the modulation of hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-12-20 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed